Shattuck Labs Initiated RECEPTIVE-CD1 Phase 2b Trial Of SL-325 In Crohn’s Disease, 12-Week Induction Data Expected In H1 2028; Expects To Start Phase 2 In Hidradenitis Suppurativa In Q4 2026
Share
Why It Matters
Shattuck Labs is testing a new medicine for two diseases. Watch how well the medicine works when results come out next year.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.